Moderna Aktie

Moderna für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A2N9D9 / ISIN: US60770K1079

<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
13.01.2025 14:14:52

Moderna Aims To Reduce 2025 Cash Costs By $1 Billion; FY25 Revenues Of $1.5 Bln To $2.5 Bln

(RTTNews) - Ahead of the presentation at the 43rd Annual J.P. Morgan Healthcare Conference later on Monday, Moderna, Inc. (MRNA) said it achieved $3.0 billion to 3.1 billion in product sales and reduced cash operating cost by over 25 percent compared to 2023 and aims to reduce 2025 cash costs by $1 billion with a plan for an additional $500 million cost savings in 2026.

Moderna added it enters 2025 with a focus on a prioritized portfolio addressing respiratory viruses, rare diseases, oncology, and latent and other viruses where there is unmet need.

Moderna now projects $1.5 billion to 2.5 billion in revenue in 2025, mostly in the second half of the year, primarily due to Spikevax.

The company also anticipates milestones across 10 prioritized programs, including up to three potential 2025 approvals and six registrational data readouts.

Analysen zu Moderna Incmehr Analysen

19.11.24 Moderna Hold Joh. Berenberg, Gossler & Co. KG (Berenberg Bank)
13.09.24 Moderna Underweight JP Morgan Chase & Co.
05.08.24 Moderna Sector Perform RBC Capital Markets
12.01.24 Moderna Outperform RBC Capital Markets
03.11.23 Moderna Buy Goldman Sachs Group Inc.
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Moderna Inc 29,78 1,90% Moderna Inc